Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp cut its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 15.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,371,039 shares of the company's stock after selling 249,603 shares during the period. Van ECK Associates Corp owned 0.28% of Elanco Animal Health worth $20,428,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Primecap Management Co. CA raised its holdings in Elanco Animal Health by 0.4% in the third quarter. Primecap Management Co. CA now owns 49,168,659 shares of the company's stock worth $552,656,000 after purchasing an additional 172,205 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Elanco Animal Health by 0.7% during the third quarter. Vanguard Group Inc. now owns 49,001,441 shares of the company's stock worth $550,776,000 after purchasing an additional 362,152 shares in the last quarter. Black Creek Investment Management Inc. lifted its holdings in shares of Elanco Animal Health by 12.8% during the 3rd quarter. Black Creek Investment Management Inc. now owns 15,523,457 shares of the company's stock valued at $174,484,000 after purchasing an additional 1,759,556 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Elanco Animal Health by 7.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 5,003,011 shares of the company's stock worth $56,234,000 after purchasing an additional 354,524 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Elanco Animal Health by 20.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,711,180 shares of the company's stock worth $52,954,000 after buying an additional 814,668 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELAN has been the topic of a number of research analyst reports. Barclays boosted their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. Morgan Stanley lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Stifel Nicolaus raised Elanco Animal Health from a "hold" rating to a "buy" rating and raised their target price for the stock from $13.00 to $20.00 in a report on Friday, January 5th. The Goldman Sachs Group lifted their price target on Elanco Animal Health from $12.50 to $14.00 and gave the company a "sell" rating in a research report on Tuesday, February 27th. Finally, TheStreet upgraded Elanco Animal Health from a "d+" rating to a "c-" rating in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of "Moderate Buy" and a consensus target price of $16.71.

Insider Buying and Selling

In other news, Director R David Hoover purchased 20,000 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the transaction, the director now owns 185,000 shares of the company's stock, valued at $2,985,900. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is currently owned by insiders.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded down $0.02 on Wednesday, reaching $13.15. The company's stock had a trading volume of 2,808,007 shares, compared to its average volume of 4,362,632. Elanco Animal Health Incorporated has a 52-week low of $7.88 and a 52-week high of $16.88. The company has a market capitalization of $6.49 billion, a P/E ratio of -5.21, a PEG ratio of 1.43 and a beta of 1.29. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average price of $15.25 and a 200-day moving average price of $13.88.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The business's revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.19 earnings per share. Analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.